We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month. The Zacks Consensus Estimate for CRSP's total revenues currently stands at $8.39 million. CRISPR Therapeutics has a positive earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 117.78%. In the last reported quarter, CRSP's earnings beat estimates by 12.27%. Other Stocks to Consider Amgen Inc. (AMGN) has an Ear ...